Breathtec Biomedical Inc. (CSE: BTH, OTCQB: BTHCF, Forum), through its wholly-owned subsidiary Nash Pharmaceuticals Inc., announced this week that its lead compound for non-alcoholic steatohepatitis NP-160 showed positive results in a recently completed study investigating its therapeutic effects.
For more, click here.
Breathtec recently acquired Nash Pharmaceuticals, a company with a risk-reduced approach to drug development through drug re-purposing
FULL DISCLOSURE: Breathtec Biomedical Inc. is a paid client of Stockhouse Publishing.